Mendus
8,15 SEK -0,65%89 investorer følger denne virksomhed
Mendus develops cancer immunotherapies with a focus on the prevention of tumor recurrence, the leading cause of cancer-related deaths globally. Indications include acute myeloid leukemia, ovarian cancer and soft tissue sarcomas. The company previously went by the name Immunicum and was renamed Mendus following the merger with the Dutch private company DCprime in 2021. Mendus today has its headquarters in Stockholm and its operational activities in Leiden, The Netherlands.
P/E (24e)
-3,19
EV/EBIT (adj.) (24e)
-2,66
P/B (24e)
0,63
Udbytteafkast, % (24e)
-
Kursmål
14.00 SEK
Anbefaling
Køb
Opdateret
18.6.2024
NASDAQ Stockholm
IMMU
Daglig lav / høj pris
8 / 8,319
SEK
Markedsværdi
410,43 mio. SEK
Aktieomsætning
278,76 t SEK
Volumen
34 t
Business risk
Valuation risk
Current
Previous
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
Antti Siltanen
Analytiker
Seneste videoer
Finanskalender
Delårsrapport
23.08.2024
Delårsrapport
08.11.2024
Årsrapport
13.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Adrianus Van Herk | 35,7 % | 35,7 % |
Flerie Invest AB | 23,9 % | 23,9 % |
Premium
This content is for our Premium customers only.
Resultatopgørelse
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Omsætning | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
vækst-% | 150,0 % | -60,0 % | 150,0 % | |||||
EBITDA | -86,9 | -132,0 | -138,5 | -133,2 | -127,3 | -123,0 | -93,0 | -95,3 |
EBIT (adj.) | -86,0 | -130,1 | -133,7 | -125,9 | -127,3 | -123,0 | -93,0 | -95,3 |
EBIT | -86,0 | -130,1 | -133,7 | -125,9 | -127,3 | -123,0 | -93,0 | -95,3 |
Overskud før skat | -89,2 | -133,4 | -138,8 | -126,9 | -128,5 | -126,0 | -96,0 | -98,3 |
Netto indkomst | -89,2 | -133,4 | -138,8 | -126,9 | -128,5 | -126,0 | -96,0 | -98,3 |
EPS (adj.) | -10,74 | -13,38 | -13,92 | -3,04 | -2,55 | -2,50 | -1,91 | -1,95 |
vækst-% | ||||||||
Udbytte | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Udbytte ratio |
Lønsomhed og afkast på kapital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -869.130,0 % | -3.298.775,0 % | -1.385.420,0 % | -1.332.210,0 % | -1.272.660,0 % | -1.229.630,0 % | -930.072,0 % | -952.637,0 % |
EBIT-% (adj.) | -860.270,0 % | -3.252.500,0 % | -1.336.940,0 % | -1.259.210,0 % | -1.272.660,0 % | -1.229.630,0 % | -930.072,0 % | -952.637,0 % |
EBIT-% | -860.270,0 % | -3.252.500,0 % | -1.336.940,0 % | -1.259.210,0 % | -1.272.660,0 % | -1.229.630,0 % | -930.072,0 % | -952.637,0 % |
ROE | -27,2 % | -20,2 % | -23,7 % | -20,8 % | -18,9 % | -21,4 % | -20,1 % | -25,8 % |
ROI | -25,3 % | -19,4 % | -22,3 % | -20,2 % | -18,7 % | -19,7 % | -15,8 % | -16,2 % |
Værdiansættelse
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Aktiekurs (SEK) | 136,32 | 78,94 | 44,40 | 10,46 | 8,15 | 8,15 | 8,15 | 8,15 |
Aktier | 8,3 | 10,0 | 10,0 | 41,8 | 50,4 | 50,4 | 50,4 | 50,4 |
Markedsværdi | 1.132,6 | 787,0 | 442,6 | 437,3 | 410,4 | 410,4 | 410,4 | 410,4 |
Enterprise value | 988,2 | 631,7 | 430,0 | 316,5 | 338,0 | 463,9 | 559,9 | 658,2 |
EV/S | 98.818,6 | 157.924,0 | 42.998,0 | 31.653,6 | 33.796,7 | 46.393,1 | 55.993,8 | 65.820,2 |
EV/EBITDA | - | - | - | - | - | - | - | - |
EV/EBIT (adj.) | - | - | - | - | - | - | - | - |
EV/EBIT | - | - | - | - | - | - | - | - |
P/E (adj.) | - | - | - | - | - | - | - | - |
P/E | - | - | - | - | - | - | - | - |
P/B | 1,7 | 1,2 | 0,9 | 0,6 | 0,6 | 0,8 | 1,0 | 1,2 |
P/S | 113.258,6 | 196.749,0 | 44.263,0 | 43.730,5 | 41.043,1 | 41.043,1 | 41.043,1 | 41.043,1 |
Udbytteprocent | ||||||||
Equity ratio | 90,7 % | 91,1 % | 82,9 % | 93,2 % | 91,6 % | 82,0 % | 67,0 % | 51,7 % |
Gearing ratio | -21,8 % | -23,6 % | -2,5 % | -17,1 % | -11,1 % | 10,2 % | 34,8 % | 74,6 % |
Kvartalsdata
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Omsætning | 0,0 | 0,0 | 0,0 | ||||||
EBITDA | -31,2 | -30,2 | -29,0 | -42,7 | -133,2 | -35,3 | -31,1 | -30,4 | -30,5 |
EBIT | -29,6 | -27,7 | -25,9 | -42,7 | -125,9 | -35,3 | -31,1 | -30,4 | -30,5 |
Overskud før skat | -30,2 | -3,3 | -52,2 | -41,2 | -126,9 | -35,6 | -31,4 | -30,7 | -30,8 |
Netto indkomst | -30,2 | -3,3 | -52,2 | -41,2 | -126,9 | -35,6 | -31,4 | -30,7 | -30,8 |
ViserAlle indholdstyper
Mendus announces collaboration with Institut Bergonié to study ilixadencel in soft tissue sarcomas
Change in number of shares and votes in Mendus AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools